ASSESSMENT OF BRAIN ESTERASE LEVELS IN PATIENTS WITH ALZHEIMER’S DISEASE

Gustavo A. A. dos Santos¹,³, Paulo Celso Pardi²

¹Senac University Center, São Paulo, Brazil
²Faculty Anhanguera of Guarulhos, São Paulo, Brazil
³Faculty of Medicine – University of Sao Paulo – USP, Brazil

(Received on Date: 2 February 2021 Date of Acceptance: 16 March 2021 Date of Publish: 19 March 2021)

E-mail: gusfarma@hotmail.com

ABSTRACT

Objectives: To prove the therapeutic efficacy of rivastigmine tartrate in transdermal form, for the reduction of blood esterase levels, in patients with Alzheimer’s disease. Methods: Forty AD patients were treated with Rivastigmine and evaluated for serum levels of AChE and BuChE esterases for 180 days. Results: We found that serum levels of BuChE in the transdermal group were significantly different (p < 0.0004) than in the oral group at 90 days. Conclusion: Rivastigmine significantly reduced BuChE levels in patients with AD.

Key Words: Alzheimer’s disease, rivastigmine, acetylcholine, esterases.
INTRODUCTION

Among the main drugs approved for the treatment of AD are esterase inhibitors. We justify its use because of the cholinergic deficits that occur during the disease. These drugs can increase the availability of synaptic acetylcholine (ACh) and inhibit its main catalytic enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE)3,4. ChE-Is are the only therapeutic class of drugs that was developed to treat Alzheimer’s and produce significant cognitive improvement in patients with AD, in addition to being very promising5. In 2003, Trinh et al.6 stated that studies that examined AD treatments focused on reducing cognitive decline using Cholinesterase inhibitors (ChE-Is). Cummings endorsed ChE-Is as the first class of drugs that are currently used for this purpose7.

The development of Alzheimer’s disease (AD) is marked by a gradual or progressive deterioration of intellectual function, a significant decline in the ability to perform everyday activities, and changes in personality and behavior, resulting in impaired memory, attention, executive function, language, and ability to perform calculations and create abstractions. Personality changes are frequent, with patients becoming more passive or aggressive and less spontaneous1,2.

In addition to ChE-Is, there are non-competitive glutamate receptor antagonists (N-methyl d-aspartate), such as memantine, which block the pathological effects of high glutamate levels8 and were the first of a novel class of drugs designed to treat moderate to severe AD. Trinh et al.6 stated that studies examining AD treatments have focused on reducing cognitive decline by using ChE-Is. Cummings endorsed ChE-Is as the first class of drugs that are currently used for this purpose7.

Rivastigmine is a well-tolerated drug that improves cognition and participation during the everyday life activities of patients in the mild to moderately severe stages of AD9. It is one of the most widely used drugs for the treatment of AD because it is capable of inhibiting both AChE and BuChE and, consequently, is more effective at increasing brain levels of ACh4. Rivastigmine in a transdermal patch is the preferred delivery method of caregivers of AD patients because it ensures increased treatment compliance10. This ChE-I represents, from a clinical perspective, an effective treatment for people with AD11.

Our study aimed to evaluate the biological effects of administering oral and transdermal rivastigmine tartrate to individuals with dementia associated with AD. We sought to identify a possible marker for assessing this treatment outcome using biochemical results and behavioral and cognitive evaluations of AD patients.

Therefore, to investigate the influence of rivastigmine tartrate using the aforementioned evaluations, we assessed the effectiveness of various formulations of rivastigmine in the pharmacological treatment of patients with AD.
METHODS
Forty participants were evaluated, with mild to moderate AD, of both sexes. All were diagnosed with Alzheimer’s Disease at the beginning of our experiment, that is, before collections. Patients were separated into groups, according to the type of treatment / pharmaceutical form of Rivastigmine Tartrate. 20 patients were in the oral group (OG), 20 patients were in the patch group (PG). Biological analyzes were based on collections of blood samples over a period of 180 days. The classification determined in the Neuropsychiatric Inventory (NPI) made it possible to track the effectiveness of treatments and the severity of the disease was classified as mild, moderate or severe. To determine the inclusion and exclusion criteria, we used a script from the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Association of Alzheimer’s Disease and Related Disorders (ADRA, 2008). AChE and BuChE esterases were analyzed according to the standards of the Clinical Laboratory Accreditation Program (PALC) of the Brazilian Society of Clinical Analyzes (SBAC). The study was approved by the Ethics and Research Committee of UNIBAN BRASIL (protocol nº 292/08). For statistical analysis, we used ANOVA, Student’s t test and the Kruskal-Wallis test in GraphPad Prism 5.

RESULTS
Biochemical assessment

AChE levels

The results of the biochemical measurements of the AChE levels in the OG and PG patients (Table 1) revealed no significant changes (p > 0.05) from 0 to 180 days across the three time periods examined.

When comparing the AChE levels after 90 days of rivastigmine tartrate treatment, we observed that the PG exhibited a small change in AChE levels; however, this difference was not statistically significant (p = 0.1764; nonparametric t-test).

BuChE levels

The results of biochemical measurements of the BuChE levels of the OG and PG patients (Table 2) revealed altered levels after 180 days of treatment when comparing the scores at day 0 using an ANOVA. A significant difference between the OG and PG patients was observed at both experimental days 0 and 90. The same difference between the groups was not observed after 180 days.

DISCUSSION
In general, studies have shown that the use of rivastigmine has been beneficial for patients with AD. These studies have emphasized the improvement of cognition and global performance. We believe that this significant improvement contributes to the stabilization of the patient’s state for several months. However, there are no beneficial effects in the more advanced stages of the disease.

Based on the scores obtained, we found a possible correlation between the results of the neurocognitive assessment and the AChE and BuChE levels, as described below. In the groups selected for this research, we found that the
differences between the oral and patch treatments were not significant after 180 days. We discovered a relationship between AD and inflammation and identified AChE and BuChE as possible markers for low-grade inflammation\textsuperscript{20}. BuChE (pseudochoolinesterase) is found in the blood, pancreas, liver, and central nervous system\textsuperscript{24,25}. AChE is found at high levels in the brain, nerves, and red blood cells. Giacobini et al. claims that AChE was found at cholinergic nerve terminals, whereas BuChE was associated with glial cells or neurons\textsuperscript{26}. Clearly establishing the role of BuChE in the normal brain or in brains with AD is still difficult\textsuperscript{27}. Our work confirmed the biochemical evaluation of ChE-Is as a possible treatment strategy, which makes it possible to monitor this disease by assessing the concentrations of these enzymes. The study did not find significant changes in blood levels of AChE between the day of the start of collections and the end after 180 days; the AChE value remained stable. We found that in patients treated with the oral form of the drug for six months, the differences showed a p-value > 0.05, and blood AChE levels in OG patients had a slight decrease during the last 90 days of treatment (between day 90 and day 180). We point out that for the drug treatment patch form, the samples showed differences with a p-value of > 0.05, with a slight decrease on treatment day 180 compared to day 0.

There was an important difference in the levels of BuChE GO and GP on day 0. The patients who used the adhesive form were different (p > 0.0004) from the patients who used the oral form. We found that the levels of average BuChE of patients who used the oral form was 4,179.5 U / L, compared to 6,618.6 U / L in patients who used the patch form. It was possible to observe during the research that patients who used the adhesive form for 90 days continued to show significant difference (p> 0.003) and, at the end of the experiment, the two groups were statistically similar, which may mean that the inhibition provoked by tartrate rivastigmine strongly influences BuChE levels. Our results confirm the pharmacological effects of rivastigmine on esterases, mainly as a BuChE inhibitor. These results were of interest because no previous study had found a correlation between the biochemical and behavioral data. Given the small changes observed in the MMSE and NPI scores, there were no significant cognitive differences.

The fluctuations were significant in the biochemical analysis of BuChE, indicating that the levels of this enzyme can be monitored by means of tests and used as a parameter in the evolution and treatment of the disease. This means support for the clinical follow-up of patients with AD.

The results of our study suggest that biomarkers can be used as potential diagnostic tools for AD, however, as previously described in the literature\textsuperscript{28}, some limitations were found during the research. The sample of only 40 patients limits the scope of observation of the effects of rivastigmine. We believe that our method of determining cholinesterases may not have accurately quantified the concentrations of these substances in the evaluated patients, so more tests should be performed.

We concluded that the transdermal form of rivastigmine (compared to the oral form) demonstrated a significant difference in
the reduction of BuChE, confirming its ability to inhibit this enzyme, normally elevated in the advanced stages of AD. The use of the pharmaceutical patch form produces similar or even better results than oral administration, in addition to providing greater convenience to patients.

### Table 1. Evaluation of AChE levels at various time periods.

|        | 0 dd       | 90 dd      | 180 dd     |
|--------|------------|------------|------------|
| Oral   | 3.20 ± 0.58| 2.99 ± 0.87| 3.39 ± 0.69|
| Patch  | 3.25 ± 0.62| 3.31 ± 0.52| 3.47 ± 0.49|

### Table 2. Evaluation of BuChE level at various time periods (values in U/L).

|        | 0dd          | 90dd         | 180dd        |
|--------|--------------|--------------|--------------|
| Oral   | 4179.5 ± 1799.2| 3782.9 ± 1798.1| 5544.6 ± 2109.5*|
| Patch  | 6618.2 ± 2095.6**| 6165.5 ± 2090.5***| 6339.4 ± 2451.1|

*p < 0.05, compared to the oral group at day 90 (ANOVA test).

**p < 0.003, compared to the oral group at day 0 (nonparametric t-test).

***p < 0.0004, compared to the oral group at day 90 (nonparametric t-test).

### REFERENCES

1. Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 2002;15:445–450.

2. Canineu, PR, Canineu RFB, Canineu PRB, Silva MC. {Terapia Multidisciplinar: uma proposta de tratamento global do idoso}. Mundo Saude 2005;29:662–665.

3. Forlenza OV. {Tratamento farmacológico da doença de Alzheimer}. Rev Psiq Clin 2005;32:137–148.

4. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer’s disease: getting on and staying on. Curr Ther Res 2003;64:216–235.

5. Minett TSC, Bertolucci PHF. {Terapia colinérgica na doença de Alzheimer}. Rev Neurociências 2000;8:11–14.

6. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210–216.

7. Cummings JL. Use of cholinesterase inhibitors in clinical practice. Am J Geriatr Psychiatry 2003;11:131–145.

8. Danysz W, Parsons CG, Möbius HJ, A Stoffler, G Quack. Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease — a
unified hypothesis on the mechanism of action. Neurotox Res 2000;2:85–98.

9. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. BMJ 1999;318:633–640.

10. Winblad B, Kawata AK, Beusterien KM et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007;22:485–491.

11. Ellis J M. Cholinesterase inhibitors in the treatment of dementia. JAOA 2005;105:145-158.

12. “Neuropsychiatric Inventory”. Available at http://www.hipocampo.org/npi.asp Accessed 03/12/2010.

13. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69:14-22.

14. Almeida OP, Crocco EI. {Percepção dos déficits cognitivos e alterações do comportamento em pacientes com doença de Alzheimer}. Arq Neuropsiquiatr 2000;58:292–299.

15. Laks J, Batista EMR, Guilherme ERL, et al. {O Mini exame do estado mental em idosos de uma comunidade – dados parciais de Santo Antônio de Pádua, Rio de Janeiro}. Arq Neuropsiquiatr 2003;61:782–785.

16. Ishizaki J, Meguro K, Ambo H, et al. A normative, community-based study of mini-mental state in elderly adults: the effect of age and educational level. J Gerontol B Psychol Sci Soc Sci 1998;53:359–363.

17. Quesada JJ, Ferrucci L, Calvani D, Valente C, Salani B, Bavazzano A. Formal education as an effect modifier of the relationship between Mini-Mental State Examination Score and IADLs disability in the older population. Aging (Milano) 1997;9:175–179.

18. Almeida O. {Mini exame do estado mental e o diagnóstico de demência no Brasil}. Arq Neuropsiquiatr 1998;56:605–612.

19. Brucki SMD, Nitrini R, Caramelli P, Bertolucci PHF, Okamoto IH. {Sugestões para o uso do mini-exame do estado mental no Brasil}. Arq Neuro-Psiquiatri 2003;61:777-781.

20. Das UM. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007;13:RA214–221.

21. Kaplay SS. Acetylcholinesterase and butyrylcholinesterase of developing human brain. Biol Neonate 1976;28:65–73.

22. Jope RS, Walter-Ryan WG, Alarcon RD, Lally KM. Cholinergic processes in blood samples from patients with major psychiatric disorders. Biol Psychiatry 1985;20:1258–1266.

23. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl-and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053–1065.

24. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer’s disease. Neurochem Res 2003;28:515–522.

25. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and
incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.